ARL8B

Across TCGA pan-cancer cohorts, ARL8B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARL8B data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARL8B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARL8B expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where ARL8B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.897	0.664	.012	21	view →
LSCC	DFS	Tertile	II,III,IV	0.927	0.546	.003	21	view →
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	18	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	18	view →
UCEC	DFS	Quartile	II,III,IV	0.436	0.904	.048	8	view →
LUAD	DFS	Tertile	II,III,IV	0.751	0.961	.028	5	view →
GBM	OS	Median	All	0.896	0.640	.014	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARL8B–HNSC (DFS)

Open the HNSC breakdown →